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Abstract Testing for hepatitis C virus (HCV) infection
may reduce the risk of liver-relatedmorbidity, by facilitating
earlier access to treatment and care. This review investigated
the effectiveness of targeted testing interventions on HCV
case detection, treatment uptake, and prevention of liver-
related morbidity. A literature search identified studies
published up to 2013 that compared a targeted HCV testing
intervention (targeting individuals or groups at increased
risk of HCV) with no targeted intervention, and results were
synthesised using meta-analysis. Exposure to a targeted
testing intervention, compared to no targeted intervention,
was associated with increased cases detected [number of
studies (n) = 14; pooled relative risk (RR) 1.7, 95 % CI 1.3,
2.2] and patients commencing therapy (n = 4; RR 3.3, 95 %
CI 1.1, 10.0). Practitioner-based interventions increased test
uptake and cases detected (n = 12; RR 3.5, 95 %CI 2.5, 4.8;
and n = 10; RR 2.2, 95 %CI 1.4, 3.5, respectively), whereas
media/information-based interventions were less effective
(n = 4; RR 1.5, 95 % CI 0.7, 3.0; and n = 4; RR 1.3, 95 %
CI 1.0, 1.6, respectively). This meta-analysis provides for
the first time a quantitative assessment of targeted HCV
testing interventions, demonstrating that these strategies
were effective in diagnosing cases and increasing treatment
uptake. Strategies involving practitioner-based interven-
tions yielded the most favourable outcomes. It is recom-
mended that testing should be targeted at and offered to
individuals who are part of a population with high HCV
prevalence, or who have a history of HCV risk behaviour.
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Meta-analysis
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Introduction
It is estimated that 185 million people have been infected
with hepatitis C virus (HCV) worldwide [1], most of whom
are unaware of their infection [2]. The burden is highest in
low- and middle-income countries (LMIC), which account
for over 80 % of cases of chronic HCV infection [1].
People living with HCV may experience considerable
barriers to accessing testing, treatment and care, particu-
larly in low-income countries [3, 4].
Populations at increased risk of HCV include people
who inject drugs (PWID) [5], people receiving medical
procedures (including transfusion of blood and blood pro-
ducts) in an unsafe setting [6, 7], men who have sex with
men (MSM) (in particular, those who are infected with
HIV) [8], and children born to mothers who have HCV [9].
Intranasal drug use and cosmetic procedures (such as tat-
tooing, body piercing, and manicures) have also been
implicated as risk factors for HCV [10]. The relative
importance of these risk factors varies depending on the
geographical setting and population studied.
Chronic HCV infection leads to an increased risk of liver
cirrhosis and liver cancer, and contributes to approximately
360,000 liver-related deaths annually [11, 12]. Testing for
and diagnosis of HCV is expected to reduce the risk of liver-
related disease, by facilitating earlier access to HCV treat-
ment and care. On this basis, European and American HCV
guidelines have recommended targetedHCV testing for high
risk groups, without necessarily the evidence to demonstrate
that early diagnosis is of benefit [13–15].
A recent narrative synthesis of eight studies concluded
that testing interventions can lead to increases in test
uptake, but other outcomes were not examined in detail
[16]. The aim of our review was to investigate and quantify
through meta-analysis the effectiveness of targeted HCV
testing interventions on patient-important outcomes,
including test uptake, case detection, uptake of HCV
treatment, and the prevention of liver-related morbidity and
mortality. The study was conducted as part of a series of
systematic reviews to inform World Health Organisation
(WHO) Guidelines on the Screening, Care, and Treatment
of Hepatitis C, with particular reference to LMIC [17].
Materials and methods
Literature search and data extraction
The review was prospectively registered with PROSPERO
(registration number CRD42013004146). A literature
search was undertaken to identify relevant articles in any
language published between January 1994 and March 2013
in the following databases: Medline, Embase, LILACS,
Cochrane library of Systematic Reviews, the NHS Eco-
nomic Evaluations Database (NHS EDD), Health Tech-
nology Assessments Database (HTA), Database of
Abstracts of Reviews of Effects (DARE), and the European
Network of Health Economic Evaluations Database (EU-
RONHEED). Search syntax is shown in Appendix 1,
briefly summarized as: Hepatitis C AND test, case-finding,
or screening. Reference lists of relevant articles were
checked for additional papers. Relevant cost effectiveness
studies were reviewed to check for empirical data that met
the inclusion criteria (Fig. 1). Foreign language articles
were translated online using Google Translate (Google,
Palo Alto USA, 2013). Due to the large number of citations
([10,000), a single reviewer conducted the citation
screening, and two reviewers carried out abstract and full-
text screening. A third reviewer was consulted on any
points of difference between the first and second reviewer.
Studies were included if they compared a targeted
testing intervention with no targeted intervention, or rou-
tine practice (Fig. 1). Included studies were assessed for
quality using the Cochrane Risk of Bias tool [18]. Missing
data on outcomes of interest were requested from primary
authors, with each author contacted twice in the case of
non-response. Data were extracted on study design, setting,
year, population, sample size, selection and characteristics
of the intervention and comparison group, type of inter-
vention, and any of the following outcomes (for both the
intervention and comparison groups): number tested for
HCV antibody, detected as HCV antibody positive, refer-
red to and attended specialist care, initiated on HCV
treatment, attained a SVR, developed cirrhosis/hepatocel-
lular carcinoma (HCC), and died from a liver-related cause.
Population denominators
The population denominator for the two testing outcomes
(test uptake and HCV antibody cases detected) was the
number of people eligible to receive the testing interven-
tion. The definition of the ‘eligible population’ varied
depending on the type of study: in the practitioner-based
studies, it was possible to record the number of people
eligible for or offered the intervention. However, for the
media/information-based studies, the number of people
exposed to the intervention was not known, and the eligible
population was therefore defined as the number of people
residing in the region where the intervention took place. If
this was not provided, the eligible population size was
estimated from other information provided in the study
(e.g. the number of GP practices in the area), and sensi-
tivity analyses were conducted around the lowest likely and
highest likely population size.
For the treatment and care outcomes (referral/attendance
at specialist, treatment uptake, and SVR), where HCV
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positivity was a pre-requisite for achieving that outcome, the
denominator was the estimated number of people in the
eligible population who were HCV antibody positive. This
was calculated in two stages: (1) first, HCV prevalence in
the study population was estimated, and (2) this prevalence
was then applied to the eligible population in the interven-
tion and comparison groups. In stage (1), HCV prevalence
was estimated as the mid-point between the lowest possible
prevalence (calculated as: number of HCV antibody positive
cases detected/eligible population) and the highest likely
prevalence, assuming that the tested population was more
likely to be HCV positive than the untested population
(calculated as: number of HCV antibody positive cases
detected/number tested), both among the intervention group.
The rationale for using the intervention group to estimate
HCV prevalence was that HCV testing in the comparison
group was more likely to relate to individuals presenting
with symptomatic disease, and thus could over-estimate the
prevalence of HCV in the eligible population. In addition,
some studies did not report the number of HCV antibody
positive cases in the comparison group.
Data synthesis
Pooled relative risks (RR) were calculated using random
effects meta-analysis (Inverse Variance [IV] method).
Heterogeneity was assessed using both I2 and stratified
analyses of the following subgroups:
1. ‘Practitioner-based targeted testing’ (defined as inter-
ventions where a health or social care practitioner was
given in-practice support to offer risk assessment and/or
HCV testing) versus ‘Media/information-based targeted
testing’ (defined as interventions comprising of televi-
sion, radio or newspaper advertisements, provision of
posters or leaflets, or invitations to information sessions
for practitioners or people at risk).
2. Testing targeted at individuals known to be PWID (e.g.
identifying PWID through medical records, or offering
tests at services for PWID), versus testing targeted at
groups at increased risk of being PWID (e.g. specific
birth cohorts, homeless populations, prisoners, psychi-
atric inpatients), or testing targeted more broadly at all
risk groups.
Sensitivity analyses were conducted to assess the effect on
the pooled effect estimates of:
1. Type of study design [randomised controlled trials
(RCT) vs. non-RCT]
2. Inclusion/exclusion of individual studies of interest
3. Estimating the eligible population denominator for
studies where this was not provided: (best estimate,
versus the lowest likely denominator or the highest
likely denominator).
4. Estimating HCV prevalence for the studies that
reported on treatment and care outcomes: (best
estimate, versus the lowest possible prevalence or the
highest likely prevalence).
Anticipated absolute effects of the intervention (i.e. the
number of additional cases detected, referred, attended
specialist, commenced therapy, and achieved a SVR) were
calculated for:
Populaon: People with a history of behaviours or exposures that place them at 
increased risk of HCV infecon
Intervenon: Targeted HCV anbody tesng. “Targeted” means idenficaon of 
individuals based either on their being part of a defined risk group (e.g. PWID, people 
living with HIV) or through quesons to elicit a history of HCV-risk behaviours
Comparison: No targeted HCV anbody tesng, or roune pracce  
Outcomes: Number of HCV anbody tests, number of HCV anbody posive tests, 
number of referrals to specialist*, number aending a specialist**, number commencing 
treatment for HCV, liver-related morbidity (liver cirrhosis, hepatocellular carcinoma, 
decompensated cirrhosis), sustained virological response (SVR), quality of life, all-cause 
mortality 
* Number of paents referred, regardless of whether aended 
**Number who aended at least one HCV specialist appointment during follow-up
Fig. 1 Population, intervention,
comparison, and outcome
(PICO) inclusion criteria
Targeted hepatitis C antibody testing interventions
123
1. The pooled study population
2. Hypothetical populations with HCV prevalence of
either 10 or 50 %.
All statistical analyses were carried out using Review
Manager Version 5.2 (Cochrane Collaboration, Copenhagen)
and GRADE Profiler Version 3.6 (GRADEWorking Group).
Outcome assessments
The quality of evidence for each outcome was assessed
using GRADE (Grading of Recommendations Assessment,
Development and Evaluation) [19].
Results
Characteristics of the included studies
Results of the literature search are shown in Fig. 2. Thir-
teen articles and one conference abstract met the inclusion
criteria, but one article was excluded [20] because a more
recent article on the same study population was identified
[21]. Three articles [22–24] reported two distinct studies
within the same article; therefore there were sixteen studies
in total.
The sixteen included studies are shown in Table 1.
There were five cluster RCTs [24–27], all of which were
assessed as having low risk of bias. There were eleven non-
RCTs, all of which were assessed as having high risk of
bias. Four were controlled trials [28–31], three were
before/after studies [23, 32], and four were time-series
analyses [21, 22, 33].
Twelve studies involved practitioner-based targeted
interventions [22–26, 28–32] while the remaining four
involved media/information-based targeted interventions
[21, 22, 27, 33]. Four studies targeted individuals with a
history of PWID, either through use of drug services [22,
25, 26], or review of medical records [29]. Five studies
targeted groups at increased risk of being PWID, which
included homeless populations [24], psychiatric inpatients
[32], and individuals within a specified birth cohort and
residing in an area of socio-economic deprivation [23, 28].
Fig. 2 Flowchart of study
selection for the systematic
review
E. J. Aspinall et al.
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Table 1 Characteristics of sixteen studies included in the systematic review
Primary
author, year,
location
Setting Study design,
(follow-up)
Target
population
Eligible
population
Intervention Comparison
Anderson
[28] UK
Two general
practices in
area of socio-
economic
deprivation
Non-
randomised
controlled
trial
(4 years)
Birth cohort
living in area of
socioeconomic
deprivation
Patients aged
30–54 years
attending
non-urgent
GP
appointments
Patients were offered a
test and given an
information leaflet.
Those accepting the
offer could attend
testing and counselling
immediately, or return
at a later date
People attending a
comparison practice
received routine care
Cullen [25]
Ireland
25 General
practices where
at least one GP
prescribed
methadone
Cluster
randomised
controlled
trial
(6 months)
Current/former
PWID
Patients
receiving
methadone
from their GP
A liaison support nurse
discussed screening
guidelines with practice
staff, provided clinical
and administrative
support, liaised with
hepatology and
addiction services, and
carried out testing at
practices
Control practices
continued with
routine care
Cullen [29]
UK
16 General
practices
serving area of
socioeconomic
deprivation
Non-
randomised
controlled
trial
(3 years)
Birth cohort of
current/former
PWID
Patients aged
30–54 years
(with records
suggesting
PWID) at
non-urgent
appointments
Patients were offered a
test and given an
information leaflet.
Participants returned to
the practice to receive
results and post-test
discussion from their
GP. One General
Practice received a staff
seminar, and the
remaining seven
received HCV
information
Control practices
continued with
routine practice, and
were not aware of
their participation in
the trial
Defossez
[21] France
Poitou–
Charentes
region,
population 1.6
million
Time series
analysis
(6 years)
All people at
increased risk
Population
residing in
intervention
area
National programme
commenced in June
1999, which included
implementation of a
targeted screening
programme and
repeated media
campaigns
The same population
prior to roll-out of the
intervention
Helsper [30]
The
Netherlands
219 General
practices across
two regions of
the Netherlands
Non-
randomised
controlled
trial (N/R)
All people at
increased risk
Population
residing in the
intervention
area
A support campaign for
GPs, which included
education sessions and
in-practice support from
practice facilitators to
carry out HCV risk
assessment. A
concurrent public
campaign (radio/
newspaper ads,
information
distribution) was
implemented in both
intervention and control
regions
Control practices
continued with
routine care. Control
region was exposed to
the same public
(media) campaign as
the intervention
region
Targeted hepatitis C antibody testing interventions
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Table 1 continued
Primary
author, year,
location
Setting Study design,
(follow-up)
Target
population
Eligible
population
Intervention Comparison
Helsper [22]
(a) The
Netherlands
Gelre-UJssel
region,
population
166,315
Time series
analysis
(4 months)
All people at
increased risk
Population
residing in the
intervention
area
Radio and newspaper
advertisements,
distribution of specially
designed posters and
brochures in public
areas where risk groups
were expected to
congregate
The same population
prior to roll-out of the
intervention
Helsper [22]
(b), The
Netherlands
Drug services in
Rotterdam
Time series
analysis
(5 months)
‘Hard drug users’
(HDU)
Estimated
population of
HDU living in
Rotterdam
26 addictions
professionals were
trained to provide HCV
counselling, which was
actively offered to
HDU. Three
information meetings
were attended by 180
HDU
The same population
prior to roll-out of the
intervention
Hickman
[26] Multi-
site, UK
14 specialist drug
clinics and six
prisons
Cluster
randomised
controlled
trial (N/R)
Current PWID
and prisoners
Drug users at
specialist
drug clinics,
or prison
inmates
HCV testing using dried
blood spot (DBS) test.
Staff training and
information on DBS,
plus on-going support
from local specialist
HCV nurses
Matched prison or drug
services received
routine care
Lacey [32]
Australia
Inpatient
psychiatry unit
at tertiary
hospital
Before/after
study (N/R)
Psychiatric in-
patients
All patients
admitted to
psychiatric
unit
A leaflet providing
information on HCV
was distributed, and a
research assistant
facilitated education/
discussion groups, and
carried out counselling
and testing
Patients admitted to the
same unit prior to the
intervention
Lewis [31]
UK
GP practices
serving
Pakistani
population
Non-
randomised
controlled
trial (N/R)
South Asian
migrant
population in
UK
South Asian
patients
registered
with GP
practices
Patients were invited by
letter to opt-out of
screening. Those who
did not opt-out were
asked to attend
screening clinics held
by Hepatologyteam at
GP surgeries
South Asian patients
were offered HCV
testing if they
attended the GP
practice
Litwin [23]
(a) USA
Three primary
care clinics in
area of socio-
economic
deprivation
Before/after
study (N/R)
All people at
increased risk
living in an
area of
deprivation
Patients
attending
primary care
clinics
Researchers placed a ‘risk
sticker’ on patient case
notes, which prompted
medical staff to ask
about HCV risk factors,
and to offer testing if
any risk factors
Patients attending the
same practices prior
to the intervention
Litwin [23]
(b) USA
Threeprimary
care clinics in
area of socio-
economic
deprivation
Before/after
study (N/R)
Birth cohort
living in an
area of socio-
economic
deprivation
Patients born
between 1945
and 1964 and
attending
primary care
clinics
Researchers placed a
‘birth cohort sticker’ on
patient case notes,
which prompted
medical staff to offer
HCV testing to all
patients born between
1945 and 1964
Patients attending the
same practices prior
to the intervention
E. J. Aspinall et al.
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Six studies targeted people with any risk factor for HCV,
either by prompting practitioners to question their patients
on a list of risk factors for HCV [23, 30], or through media
campaigns advising people at risk to present for testing [21,
22, 27, 33]. The remaining study targeted a South Asian
community living in the UK [31].
Findings of the studies
Sixteen studies reported on test uptake and fourteen reported
on HCV antibody positive cases detected in both the inter-
vention and comparison groups (Table 2). Most studies
reported that testing interventions increased the number of
tests and the number of cases detected, except Lacey et al.
and Helsper et al. [22] (b) (which did not report on case
detection in the comparison group) and Roudot-Thoraval
et al. (where uptake and case detection decreased); the latter
study provided information leaflets and posters about HCV
risk factors to randomly selectedGP surgeries, and continued
with routine practice in the comparison practices. The
number of individuals needed to test to detect a single HCV
antibody positive case varied depending on the population
group targeted for testing: it was highest when all risk groups
were targeted (range 19–118), and lowestwhen either groups
at increased risk of being PWID (8–36) or individual PWID
(range 1–4) were targeted.
Four studies reported on treatment and care outcomes,
all of which involved practitioner-based interventions [25,
28, 29, 31]. All reported an increase in the number of
referrals, attendances, and treatment uptake in the inter-
vention compared to the comparison group. Across the four
intervention groups, 167 individuals were diagnosed as
HCV antibody positive (including both those RNA positive
and negative), of which 91 were referred to a specialist, 75
attended, and 13 commenced HCV treatment within a
median of 2 years of follow-up. Assuming that 70 % of
HCV antibody positive individuals were HCV RNA posi-
tive [34] (as HCV RNA results were not available for all
studies), the aforementioned results would equate to 78, 64,
and 11 % of patients with chronic HCV being referred,
attending, and commencing treatment, respectively.
Relative effects of targeted testing interventions
Exposure to a targeted testing intervention, compared to no
targeted intervention, was associated with increased num-
ber of people tested for HCV [number of studies (n) = 16,
pooled RR 2.9, 95 % confidence interval (CI) 2.0, 4.2;
I2 = 100 %], HCV antibody cases detected (n = 14;
Table 1 continued
Primary
author, year,
location
Setting Study design,
(follow-up)
Target
population
Eligible
population
Intervention Comparison
Roudot-
Thoraval
[27] France
184 General
practices in the
Creteil region
Cluster
randomised
controlled
trial (N/R)
All people at
increased risk
Population
residing in the
intervention
area
Provision of posters and
leaflets in GP surgeries,
informing patients of
the risk factors for HCV
Patients attending GP
surgeries where the
posters and leaflets
were not provided
Sahajian [33]
France
3,052 General
practitioners
and private
practices in
Lyon region
Time series
analysis
(12 months)
All people at
increased risk
Population
residing in the
intervention
area
A guide on HCV testing
was mailed to private
practitioners. GPs and
laboratory physicians
were invited to
workshops and training
sessions on HCV testing
Population of the same
region prior to the
roll-out of the
intervention
Sahajian [24]
(a) France
12 Homeless
hostels
providing long-
term
accommodation
Cluster
randomised
controlled
trial (N/R)
Homeless
population
Individuals
staying at
homeless
hostels
Group information
sessions for residents
were followed by
referral, if interested, to
a Health Centre where a
medical check-up and
HCV testing were
carried out
Individuals staying at
comparison shelters
received routine care
Sahajian [24]
(b) France
12 Homeless
hostels
providing long-
term
accommodation
Cluster
randomised
controlled
trial (N/R)
Homeless
population
Individuals
staying at
homeless
hostels
Group information
sessions were followed
by on-site medical
check-ups and HCV
testing for those who
were interested
Individuals staying at
comparison shelters
received routine care
N/R not reported
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pooled RR 1.7, 95 % CI 1.3, 2.2; I2 = 76 %), referrals to a
specialist (n = 1; RR 3.0, 95 % CI 1.8, 5.1), attendance
with a specialist (n = 1; RR 3.7, 95 % 1.9, 7.0), and cases
commencing treatment (n = 4; RR 3.3, 95 % CI 1.1, 10.0;
I2 = 0 %) (Table 3). Of the studies which reported on the
number of patients achieving a SVR (over an average of
2 years of follow-up), there was no significant difference
(n = 2; RR 1.4, 95 % CI 0.3, 7.1; I2 = 0 %) in targeted,
compared to no targeted HCV testing intervention. The
synthesised evidence for both the test uptake and cases
detected outcomes was rated as moderate quality, because
the evidence was derived from RCTs and observational
studies (with minimal impact of study design on effect
size—see Appendix 2), but study effect sizes were incon-
sistent. The synthesised evidence for the referral, atten-
dance, and treatment outcomes was also rated as moderate
quality, because the evidence was derived mainly from
RCTs, but the available data was sparse.
Sensitivity analyses (Appendix 2)
1. Inclusion of non-RCT evidence potentially over-esti-
mated the effect estimate for two outcomes—referral
to specialist, and attendance with a specialist—and so
data synthesis for these outcomes was thereafter
restricted to RCT evidence.
2. Inclusion of Defossez [21], which used a different length
of follow-up for the pre- and post-intervention periods,
had minimal impact on pooled relative risks and hetero-
geneity, and therefore was included in data synthesis.
3. Varying the size of the eligible population denomina-
tor across a range of likely values (for Roudot-
Thoraval [27], where the size of the eligible population
was not known) had no impact on pooled effect size or
heterogeneity, and therefore the best estimate of the
denominator was used.
4. Estimating HCV prevalence across a likely range of
values (for the studies reporting on HCV treatment and
care outcomes) had minimal impact on pooled effect
sizes and heterogeneity, and therefore the best estimate
of HCV prevalence was used.
Stratified analyses
A practitioner-based approach to targeted testing, com-
pared to no targeted testing, increased both the number of
people tested for HCV and the number who tested positive
for HCV (n = 12; RR 3.5, 95 % CI 2.5, 4.8; I2 = 94 %,
and n = 10; 2.2, 95 % CI 1.4, 3.5; I2 = 78 % respectively)
(Table 4). A media/information-based approach to targeted
testing, compared to no targeted testing, was less effective
in increasing the number of people tested for HCV and theT
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number who tested positive (n = 4; RR 1.5, 95 % CI 0.7,
3.0; I2 = 100 %, and n = 4; 1.3, 95 % CI 1.0, 1.6;
I2 = 58 % respectively) (Fig. 3).
Targeting of individuals known to be PWID, compared
to no targeted testing, increased the number of tests, and
the number who tested positive for HCV (n = 4; RR 3.4,
95 % CI 1.7, 6.8; I2 = 91 %, and n = 3;3.1, 95 % CI 1.4,
7.1; I2 = 93 % respectively). Targeting of specific groups
at increased risk of being PWID increased the number of
tests (n = 6; RR 5.6, 95 % CI 2.8, 11.4; I2 = 97 %), more
than the number of positive tests (n = 5; RR 1.8, 95 % CI
0.9, 3.6; I2 = 65 %). Targeted testing of individuals with
any risk factor for HCV, compared to no targeted testing,
was less effective in both increasing the number of tests
(n = 6; RR 1.6, 95 % CI 0.9, 2.8; I2 = 100 %) and the
number of positive tests (n = 6; 1.3, 95 % CI 1.1, 1.6;
I2 = 36 %) (Fig. 4). Due to the small number of studies
that reported on the treatment and care outcomes, stratified
analyses were conducted for testing outcomes only.
Anticipated absolute effects of targeted testing
interventions
Targeted HCV testing interventions, compared to no tar-
geted testing, are anticipated to increase the number of
people tested for HCV antibody by 112 (95 % CI 59–186)
per 10,000 eligible population, and the number of HCV
antibody positive cases detected by 1 (95 % CI 0–2) case
per 10,000 eligible population. Among the HCV positive
population, testing interventions are anticipated to increase
the number of people attending specialist appointments by
3,683 (95 % CI 1,274–8,294) per 10,000, and to increase
the number commencing HCV treatment by 197 (95 % CI
53–785) per 10,000 population.
Discussion
This systematic review and meta-analysis provides for the
first time a quantitative assessment of the effectiveness of
Table 3 Pooled relative and absolute effects of HCV testing interventions
Outcome (median
length of follow-up)
Population
(studies)
Effect
size
(95 %
CI)
I2 Baseline risk
per 10,000
population
Anticipated
absolute effects
per 10,000
population
(95 % CI)
Anticipated absolute
effects per 10,000 if
HCV prevalence is
10 %
Anticipated absolute
effects per 10,000 if
HCV prevalence is
50 %
Tested for HCV
among the eligible
population (N/A)
7,435,283
(16 studies)
2.90
(2.01,
4.17)
100 % 59 tests
conducteda
112 more HCV
antibody tests
(from 59 more to
186 more)a
N/A N/A
HCV positive cases
detected among the
eligible population
(N/A)
7,424,451
(14 studies)
1.66
(1.27,
2.16)
76 % 2 cases
detecteda
1 more case
detected (from 0
more to 2 more)a
5 more cases
detected (from 2
more to 8 more)
23 more cases
detected(from 9
more to 40 more)
Referral to specialist
among HCV
positive population
(6 months)
138
(1 study)
3.01
(1.79,
5.07)
N/A 2,000 referrals
to specialistb
4,020 more
referrals (from
1,580 more to
8,140 more)b
433 more referrals
(from 157 to 913
more)
1,298 more referrals
(from 470 to 2,739
more)
Attendance at
specialist among
HCV positive
population
(6 months)
138 (1 study) 3.66
(1.92,
6.99)
N/A 1,385 attending
a specialistb
3,683 more
attendances
(from 1,274
more to 8,294
more)b
287 more
attendances (from
94 to 665 more)
1,722 more
attendances(from
561 to 3,991 more)
Commenced
treatment among
HCV positive
population
(2 years)
683
(4 studies)
3.25
(1.06,
9.95)
0 % 88
commencing
treatmentb
197 more
commencing
(from 53 more to
785 more)b
17 more
commencing (from
0 more to 67more)
67 more
commencing (from
1 more to 268
more)
SVR among HCV
positive population
(3 years, 6
months)
515
(2 studies)
1.35
(0.26,
7.09)
0 % 76 achieving
an SVRb
27 more achieving
SVR (from 56
fewer to 465
more)b
2 more SVRs (from
5 fewer to 43
more)
9 more SVRs (from
21 fewer to 170
more)
Bold type denotes p value\ 0.05
N/A not applicable
a Per 10,000 population eligible for testing
b Per 10,000 HCV positive population
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targeted HCV testing interventions in increasing the uptake
of HCV testing, treatment, and care. Our review examined
more outcomes and identified more primary studies than
previous reviews of testing interventions [16, 35], and also
included non-English language and economic evaluation
studies. Targeted testing interventions—comprising both
practitioner-based and media/information-based strate-
gies—were associated with increased test uptake (pooled
RR 2.9, 95 % CI 2.0, 4.2), although the association with
HCV case detection was less marked (pooled RR 1.7, 95 %
CI 1.3, 2.2). This is to be expected even in the most
effective of testing interventions, where testing on the basis
of risk (rather than on the basis of symptoms) will increase
the proportion of negative tests conducted. Targeted testing
interventions were also associated with increased HCV
treatment uptake (pooled RR 3.3, 95 % CI 1.1, 10.0), but
there was insufficient evidence for improvements in SVR
or liver-related morbidity. The latter may be due to the
short periods of follow-up used by the primary studies
included in the review, and their focus on immediate out-
comes of test uptake and case detection. While further
studies examining the longer-term impact of testing would
be desirable, such studies are impractical and other data
showing treatment leads to SVR, reduced morbidity, and
improved survival are already very strong [36, 37].
The success of targeted HCV testing interventions was
dependent on both the risk-group targeted, and the type of
strategy adopted. Targeting of individuals known to be
PWID was associated with increased test uptake and case
detection, whereas targeting individuals with any HCV risk
factor was less effective. This may be due to the difference
in estimated HCV prevalence between studies targeting
individual PWID (range 16.8–70.2 %) and studies target-
ing individuals with any HCV risk factor (range
0.4–3.0 %).
Studies targeting groups at increased risk of PWID (e.g.
homeless persons, or selected birth cohorts) improved test
uptake, but there was less evidence for an increase in case
detection. This could be because within a group-targeting
strategy, those individuals at lower risk are more likely to
agree to testing, whereas those at higher risk may not
respond to the offer of a test unless they are questioned
about their history of risk behaviour.
Practitioner-based studies were effective in increasing
test uptake and cases detected, but media/information-
based studies were less effective. There was limited detail
Fig. 3 Forest plots comparing targeted HCV testing interventions versus no targeted testing intervention by type of targeted testing: outcome;
HCV antibody cases detected
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of the types of interventions employed in the media/
information-based studies, but it may be that these inter-
ventions were not sufficiently intensive, or only raised
awareness of HCV, rather than providing practical infor-
mation on testing programmes. Information campaigns rely
on individuals to self-assess their risk, and former PWID in
particular may not self-identify as being part of a risk
group, particularly if their exposure was not recent. It has
also been suggested that the impact of media campaigns
may be short-lived [38], and therefore any positive effects
may have been missed in studies that evaluated the cam-
paign some months or years later [21, 22, 33].
There was considerable heterogeneity across the two
testing outcomes (test uptake and HCV cases detected),
which could not be accounted for by the variables exam-
ined in the stratified analyses. A review of the forest plots
for these outcomes demonstrated that this heterogeneity
derived from variable precision and different effect sizes
pointing in the same direction, rather than from directly
contradictory findings. The variable precision observed
here is due to the vastly different sizes of population
denominator used by the different studies (from small
clinic-based studies to population-level interventions),
leading to very narrow confidence around some estimates,
and thus minimal cross-over with other studies. The range
in positive effect sizes is likely to be due to the variability
in targeting strategies used, as well as the heterogeneity of
the intervention and comparison groups across the studies.
For example, in the two studies that targeted PWID through
GP practices, Cullen et al. [25] identified their target group
by asking GPs to recruit current methadone users, whereas
Cullen et al. [29] identified PWID through medical records
that suggested a history of injecting. The testing interven-
tion in Cullen et al. [25] appeared considerably less
effective, because baseline HCV testing among methadone
users in GP settings was already very high. Similarly, of
Fig. 4 Forest plots comparing targeted HCV testing interventions versus no targeted testing intervention by target group: outcome; HCV
antibody cases detected
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two studies that targeted a birth cohort living in an area of
socioeconomic deprivation, Anderson et al. was more
successful in detecting HCV cases than Litwin et al.,
possibly due to less routine testing and higher HCV prev-
alence in the Anderson et al. study.
Across the four studies that reported on treatment and
care outcomes [25, 28, 29, 31], 64 % of the estimated
chronic HCV population attended a specialist appointment,
but only 11 % commenced treatment within a median of
2 years of follow-up. While allowing for the short follow-
up period, this suggests that uptake of treatment (in the
context of interferon based therapies) within testing inter-
ventions is likely to be low, and considerably lower than
assumptions used in various studies modelling the cost-
effectiveness of testing [22, 39, 40]. In comparison,
attendance at specialist appointments was relatively high,
suggesting that patients who attended appointments were
assessed as unsuitable for treatment, due to patient pref-
erence, provider preference, or co-morbidities such as
mental health or substance use. It is important that testing
interventions provide adequate pre-test counselling, to
allow patients to understand the implications of a positive
test and the treatments available. In addition, treatment
services need to be ready to manage ‘screened’ popula-
tions, who may be inherently different to patients who have
presented spontaneously for testing.
The majority of the targeted interventions reported in
this review were conducted in General Practice settings, of
which most were conducted in countries (UK, France, and
Ireland) where primary healthcare provision is universal.
Table 4 Stratified analysis
Outcome Stratification Subgroup No. of
studies
Studies included Effect size
(95 % CI)
Heterogeneity
(I2) (%)
Tested for HCV Type of
targeted
testing
Practitioner-based 12 Anderson [28], Cullen [25], Cullen
[29], Helsper [30], Helsper [22] (b),
Hickman [26], Lacey [32], Lewis
[31], Litwin [23] (a, b), Sahajian
[24] (a, b)
3.47 (2.52,
4.79)
94
Media/information-
based
4 Defossez [21], Helsper [22] (a),
Roudot-Thouraval [27], Sahajian
[33]
1.47 (0.71,
3.03)
100
Target group Individuals known to be
PWIDa
4 Cullen [25], Cullen [29], Helsper
[22] (b), Hickman [26]c
3.43 (1.73,
6.80)
91
Groups at increased risk
of being PWIDb
6 Anderson [28], Hickman [26]c,
Lacey [32], Litwin [23] (b),
Sahajian [24] (a, b)
5.61 (2.75,
11.44)
97
All HCV risk groups 6 Defossez [21], Helsper [30], Helsper
[22] (a), Litwin [23] (a), Roudot-
Thoraval [27], Sahajian [33]
1.57 (0.89,
2.77)
100
HCV positive
cases detected
Type of
targeted
testing
Practitioner-based 10 Anderson [28], Cullen [25], Cullen
[29], Helsper [30], Hickman [26],
Lewis [31], Litwin [23] (a, b),
Sahajian [24] (a, b)
2.24 (1.44,
3.48)
78
Media/information-
based
4 Defossez [21], Helsper [22] (a),
Roudot-Thouraval [27], Sahajian
[33]
1.26 (0.97,
1.64)
58
Target group Individuals known to be
PWIDa
3 Cullen [25], Cullen [29], Helsper
[22] (b), Hickman [26]c
3.12 (1.37,
7.11)
93
Groups at increased risk
of being PWIDb
5 Anderson [28], Hickman [26]c,
Litwin [23] (b), Sahajian [24] (a, b)
1.81 (0.91,
3.59)
65
All HCV risk groups 6 Defossez [21], Helsper [30], Helsper
[22] (a), Litwin [23] (a), Roudot-
Thoraval [27], Sahajian [33]
1.30 (1.07,
1.57)
36
Stratification for referral, attendance, treatment commencement and SVR outcomes was not attempted due to the small number of studies
Bold type denotes p value\ 0.05
a Identified through services for PWID or by review of medical records
b Includes the following groups: homeless, prisoners, psychiatric inpatients, birth cohort living in an area of socio-economic deprivation
c Hickman [26] studied two different groups (PWID at drug services, and prisoners) and therefore results are stratified for this subgroup analysis
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Current or former PWID are likely to have better access to
universal health systems, and this may have contributed to
the success of testing interventions in these settings. It
should also be noted that all of the primary studies included
in this review were based in high-income countries, and the
applicability of these results to LMIC is therefore uncer-
tain. Although there is a lack of evidence for targeted HCV
testing interventions in these settings, a recent review of
HIV testing interventions in LMIC concluded that pro-
vider-initiated HIV testing could be effective in increasing
test uptake, although the impact on treatment uptake and
risk behaviour was equivocal [41]. The HIV-testing studies
were based in a number of countries across sub-Saharan
Africa and Asia, and delivered testing through hospital
outpatient clinics, methadone programmes, and sexual
health services. It is therefore probable that HCV testing
interventions would be similarly feasible in a range of
different LMIC settings. In addition, it might be expected
that the relative effect of testing interventions would be
even greater in LMIC settings than reported here, given
that baseline testing and treatment is likely to be very low.
It is anticipated that approaches to HCV case-finding
will undergo considerable changes in the future, as a result
of advances in HCV testing, treatment, and care. These
include the introduction of rapid testing (providing access
to on-the-spot testing and diagnosis for hard-to-reach
populations), and the advent of new interferon-free thera-
pies, which will have increased tolerability and efficacy
compared to previous regimens. As knowledge and
awareness of these developments increase, it is likely that
there will be increased willingness, from both providers
and patients, to test for HCV and to seek assessment for
treatment. This review captures the effectiveness of testing
interventions during the era of interferon-based therapies,
and the effect sizes quoted here are therefore likely to
under-estimate the future effectiveness of testing inter-
ventions in the interferon-free era.
This meta-analysis provides for the first time a quanti-
tative assessment of targeted HCV testing interventions,
demonstrating that these strategies were effective in diag-
nosing cases and increasing treatment uptake. Strategies
involving practitioner-based interventions yielded the most
favourable outcomes. While evidence is lacking on longer-
term outcomes, data from studies of treated patients pro-
vides strong evidence that increased treatment uptake
would translate into improved SVRs, and subsequently to
reductions in liver-related morbidity. It is therefore rec-
ommended that testing should be targeted at and offered to
individuals who are part of a population with high HCV
prevalence, or who have a history of HCV risk behaviour.
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